• News
  • SAN DIEGO
  • BioTech

Sanofi, Isis win FDA advisers' support for cholesterol treatment

Sanofi and San Diego-based Isis Pharmaceuticals Inc. (Nasdaq: ISIS) won the support of U.S. regulatory advisers for its drug that treats a hyper form of high cholesterol in people with a rare genetic disease.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Isis Pharmaceuticals Inc.

Company Website

1896 Rutherford Road
Carlsbad, CA 92008

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ISIS
45.00
  2.63  
+ 6.21%
2,687,535,000
62.66
22.25

Insider Trade Data

Date Insider Shares Type Value
10/17/2014 Isis Pharmaceuticals Inc 12,100 Sell $483,939
10/03/2014 Crooke, Stanley T 36,000 Sell $1,386,860
10/03/2014 Crooke, Stanley T 36,000 Exchange $507,630
10/03/2014 Isis, Pharmaceuticals Inc 10,300 Sell $394,118
10/03/2014 Isis Pharmaceuticals Inc 10,300 Sell $394,118

Isis Pharmaceuticals Inc. Executive(s):

Stanley Crooke

  • Chief Executive Officer, Founder, President, Chairman

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing
SIC - 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Subscribe Today!